Edition:
United Kingdom

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

85.49USD
19 Jan 2018
Change (% chg)

$-0.33 (-0.38%)
Prev Close
$85.82
Open
$86.22
Day's High
$86.28
Day's Low
$85.32
Volume
2,329,086
Avg. Vol
919,922
52-wk High
$89.07
52-wk Low
$74.00

Select another date:

Thu, Dec 14 2017

BRIEF-NSAV Subsidiary Signs Agreement With Eli Lilly

* NSAV SUBSIDIARY SIGNS MAJOR AGREEMENT WITH ELI LILLY AND COMPANY

Lilly's 2018 forecast beats on strength of new drugs

Eli Lilly and Co on Wednesday forecast 2018 profit and revenue ahead of Wall Street estimates on strong demand for recently launched drugs such as Trulicity and Taltz.

Lilly forecasts 2018 profit largely above estimates

Dec 13 Eli Lilly and Co on Wednesday forecast 2018 earnings largely above analysts' estimates in part due to strong demand for recently launched products such as diabetes drug Trulicity and psoriasis drug Taltz.

BRIEF-FDA Accepts Biologics License Application (BLA) To Review Galcanezumab For The Prevention Of Migraine In Adults

* FDA ACCEPTS BIOLOGICS LICENSE APPLICATION (BLA) TO REVIEW GALCANEZUMAB FOR THE PREVENTION OF MIGRAINE IN ADULTS

BRIEF-Novo Nordisk expects to launch new diabetes drug in Japan during H1 2018

Dec 6 NOVO NORDISK A/S CHIEF SCIENTIFIC OFFICER MADS KROGSGAARD THOMSEN MADE FOLLOWING COMMENTS DURING AN INVESTOR CALL FOLLOWING U.S. APPROVAL OF DIABETES DRUG OZEMPIC:

FDA approves Novo Nordisk diabetes drug Ozempic

The U.S. Food and Drug Administration on Tuesday approved Novo Nordisk A/S's diabetes drug Ozempic, setting the stage for a heated battle with Eli Lilly & Co's Trulicity.

UPDATE 3-U.S. FDA approves Novo Nordisk diabetes drug Ozempic

Dec 5 The U.S. Food and Drug Administration on Tuesday approved Novo Nordisk A/S's diabetes drug Ozempic, setting the stage for a heated battle with Eli Lilly & Co's Trulicity.

BRIEF-Eli Lilly And Co reports 17.5 pct passive stake in Leap Therapeutics ‍​as of Nov 14

* Eli Lilly And Co reports 17.5 percent passive stake in Leap Therapeutics Inc‍​ ‍​as of November 14 - SEC Filing Source text: (http://bit.ly/2BcO2L7) Further company coverage:

Lilly mulls sale, other options for animal health business

Eli Lilly and Co said on Tuesday it is considering the sale of its Elanco animal health business and expressed optimism that its rejected rheumatoid arthritis drug would pass muster with U.S. regulators when it resubmits its application.

BRIEF-Lilly "very optimistic" on U.S. prospect for arthritis drug

* Eli Lilly says "very optimistic" on U.S. prospect for arthritis drug baricitinib; still sees resubmission to FDA by January Source text for Eikon: Further company coverage: (Reporting By Bill Berkrot)

Select another date: